Eli Lilly's Wegovy Competitor Is Causing Supply Constraints: What It Means for the Stock

Things are going exactly as planned for the biotech giant.The battle for leadership in the anti-obesity drug market is heating up. Eli Lilly (LLY 2.10%) and Novo Nordisk are the two undisputed frontrunners, but many other drugmakers are looking to challenge the status quo. Novo Nordisk's Wegovy, first approved in the U.S. in 2021, has been growing its sales rapidly.However, Eli Lilly launched a competing product, Zepbound, late last year. Analysts have incredibly high hopes for Zepbound, and the medicine ha ...